Why Attend the Novel CNS Biomarker Summit Europe?
As biomarkers become increasingly central to CNS drug development, there has never been a more important time to understand how they can be successfully implemented across the development pipeline.
Join experts from Roche, Lundbeck, UCB, Saniona, Monument Therapeutics, NRG Therapeutics and other leading biopharma as they share practical strategies for discovering, validating and implementing the next generation of fluid, imaging and digital biomarkers.
Exchange insights across Alzheimer's, Parkinson's, ALS, schizophrenia and beyond, to leave equipped to build more robust, data-driven biomarker programmes.
Why Join the Workshop Day?
Join experts from Roche, PTC Therapeutics, UCB, Immunic Therapeutics, HuntX Pharma and more who have already secured their places on the workshop day. Get ahead of the networking, build valuable connections early and collaborate with industry peers to tackle shared challenges in CNS biomarker development.
Get ahead of the networking and build meaningful connections in a smaller, more interactive environment.
Engage directly with industry experts from Bial and UCB to discuss your specific biomarker challenges.
Move beyond presentations and collaboratively tackle real challenges in biomarker validation, harmonisation and implementation.
Exchange practical strategies with peers and discover how other organisations are overcoming similar barriers.
Walk away with actionable insights to strengthen your own biomarker programmes.
Maximise your three-day experience by establishing valuable relationships before the main conference begins.
Unmissable Event Highlights
Gain First Access to the Next Wave of CNS Biomarkers
Explore the latest advances in fluid, imaging and digital biomarkers, from α-synuclein seed amplification assays and toxic oligomers to digital cognitive and EEG biomarkers shaping the future of CNS drug development.
Hear the Data Behind the Biggest Breakthroughs
Learn directly from leading biopharma such as Roche, and Saniona as they share real-world case studies on discovering, validating and implementing biomarkers to improve patient selection, demonstrate target engagement and strengthen clinical decision-making.
Solve the Challenges Holding Biomarkers Back
Discover practical strategies to overcome assay harmonisation, regulatory expectations, biomarker qualification and cross-study variability to generate robust, regulatory-ready data.
Connect with Europe's CNS Biomarker Community
Network with biomarker, preclinical, translational, precision, mulitomic, neuroscience and clinical development leaders driving the next generation of neurodegenerative drug development.
Shape the Future of Biomarker-Driven Drug Development
Join discussions on the technologies, validation strategies and collaborative approaches that are redefining how CNS therapies are developed across Alzheimer's, Parkinson's, ALS, schizophrenia and beyond.
Attending Companies Include
Explore the Full Three-Day Agenda
- Share with colleagues to plan your attendance
- Preview exclusive industry case studies covering 6+ CNS indications
- Discover the 18+ expert speaker line-up and 2 pre-conference workshops
- View the expected seniority and audience composition
- Explore 8+ hours of in-person networking opportunities
Explore the Agenda
Discover the latest case studies and practical strategies shaping the future of CNS biomarker development from Lundbeck, Roche, UCB & more.
Partner With Us
Position your brand alongside Europe's leading biomarker innovators and connect with decision-makers actively seeking new technologies and partners.
Join Biopharma Experts
Exchange ideas with biomarker, translational medicine and clinical development leaders tackling the biggest challenges in neurodegenerative drug development.